XML 57 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Reporting
 6 Months Ended
Jun. 30, 2014
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting
The Company evaluates performance based on the operating income (loss) of the respective business segments. The segment results may not represent actual results that would be expected if they were independent, stand-alone businesses. Segment information is as follows (in thousands):
Balance Sheet Data:
As of June 30, 2014
 
Ligand
 
CyDex
 
Total
Total assets
$
32,577

 
$
67,270

 
$
99,847

 
 
 
 
 
 
 
As of December 31, 2013
 
Ligand
 
CyDex
 
Total
Total assets
$
38,408

 
$
66,305

 
$
104,713

 
 
 
 
 
 
Operating Data:
For the three months ended June 30, 2014
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
$
5,692

 
$
4,916

 
$
10,608

Depreciation and amortization expense
68

 
601

 
669

Operating (loss) income
(867
)
 
2,225

 
1,358

Interest expense, net
181

 
—

 
181

Income tax expense from continuing operations
45

 
2

 
47

 
 
 
 
 
 
 
For the three months ended June 30, 2013
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
3,820

 
5,760

 
$
9,580

Depreciation and amortization expense
59

 
610

 
$
669

Write-off of in-process research and development
—

 
480

 
$
480

Operating (loss) income
(1,200
)
 
2,714

 
$
1,514

Interest expense, net
453

 
—

 
$
453

Income tax expense (benefit) from continuing operations
(145
)
 
35

 
$
(110
)
Gain on sale of Avinza Product Line before income taxes
2,397

 
—

 
$
2,397

 
 
 
 
 
 
 
For the six months ended June 30, 2014
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
12,483

 
$
14,083

 
$
26,566

Depreciation and amortization expense
134

 
1,203

 
1,337

Operating (loss) income
(938
)
 
7,396

 
6,458

Interest expense, net
429

 
—

 
429

Income tax expense from continuing operations
6

 
—

 
6

 
 
 
 
 
 
 
For the six months ended June 30, 2013
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
$
10,057

 
$
11,174

 
$
21,231

Depreciation and amortization expense
117

 
1,222

 
1,339

Write-off of in-process research and development
—

 
480

 
480

Operating income
198

 
5,249

 
5,447

Interest expense, net
1,361

 
—

 
1,361

Income tax expense (benefit) from continuing operations
(205
)
 
29

 
(176
)
Gain on sale of Avinza Product Line before income taxes
2,588

 
—

 
2,588